4/18
04:45 pm
ikt
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs [Yahoo! Finance]
Low
Report
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs [Yahoo! Finance]
4/18
04:30 pm
ikt
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Low
Report
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
4/3
08:24 am
ikt
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension [Yahoo! Finance]
High
Report
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension [Yahoo! Finance]
4/3
08:05 am
ikt
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Medium
Report
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
4/2
10:40 am
ikt
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/27
04:24 pm
ikt
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity [Yahoo! Finance]
Medium
Report
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity [Yahoo! Finance]
3/27
04:15 pm
ikt
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Medium
Report
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
3/7
08:41 am
ikt
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders [Yahoo! Finance]
Low
Report
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders [Yahoo! Finance]
3/7
08:30 am
ikt
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Medium
Report
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
3/5
11:02 am
ikt
Inhibikase Therapeutics, Inc. (NYSE: IKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Medium
Report
Inhibikase Therapeutics, Inc. (NYSE: IKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
2/28
04:13 pm
ikt
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro [Yahoo! Finance]
Medium
Report
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro [Yahoo! Finance]
2/28
04:05 pm
ikt
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Medium
Report
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
2/15
11:53 am
ikt
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]
Low
Report
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]
2/13
08:23 am
ikt
New Strong Buy Stocks for February 13th [Yahoo! Finance]
Low
Report
New Strong Buy Stocks for February 13th [Yahoo! Finance]
2/8
08:05 am
ikt
New Strong Buy Stocks for February 8th [Yahoo! Finance]
Low
Report
New Strong Buy Stocks for February 8th [Yahoo! Finance]
2/7
08:10 am
ikt
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers [Yahoo! Finance]
Low
Report
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers [Yahoo! Finance]
2/7
07:55 am
ikt
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
High
Report
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
1/29
11:34 am
ikt
Inhibikase Therapeutics Shares Up 11% Following Positive Data for Parkinson's Treatment [MarketWatch]
Low
Report
Inhibikase Therapeutics Shares Up 11% Following Positive Data for Parkinson's Treatment [MarketWatch]
1/29
09:22 am
ikt
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib [Yahoo! Finance]
Medium
Report
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib [Yahoo! Finance]
1/29
09:05 am
ikt
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
Medium
Report
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib